摘要
目的观察阿米卡星联合氨溴索雾化吸入治疗脑卒中相关性肺炎(SAP)的疗效。方法选取住院SAP患者48例,随机分为对照组19例和观察组29例。对照组患者给予脑卒中常规治疗、抗感染和氨溴索雾化吸入,观察组在此基础上增加阿米卡星雾化吸入。治疗7天后评价两组患者的有效率和致病菌清除率以及两组患者治疗前后的临床肺部感染评分(CPIS)、PaO2/FiO2和神经功能缺失程度评分(NIHSS)。结果观察组治疗有效率高于对照组,两组致病菌清除率无统计学差异。治疗后,两组患者CPIS评分和PaO2/FiO2均好于治疗前,在观察组好于对照组;与治疗前比较,治疗后NIHSS评分在观察组明显降低,在对照组降低不明显,两组比较差异无统计学意义。结论阿米卡星联合氨溴索雾化吸入作为SAP的辅助治疗能够更有效的控制肺部感染、帮助促进肺功能和神经功能的恢复。
Objective To observe the clinical effect of aerosolized amikacin and ambroxol treatment on stroke‐associated pneu‐monia（SAP） .Methods 48 patients with SAP met the inclusion criteria were randomly divided into control group and observa‐tion group .19 cases in the control group were given stroke routine treatment ,anti‐infection and aerosolized ambroxol .29 cases in the observation group were given aerosolized amikacin additionally .After 7 days ,the total effective rate ,bacterial clearance rate , clinical pulmonary infection score（CPIS） ,PaO2/FiO2 and NIHSS score were compared between the two groups before and after the treatment ,respectively .Results The total effective rate of observation group was higher than the control group ,there was no significant difference in the bacterial clearance rate between the two groups .After the treatment ,CPIS and PaO2/FiO2 in the two groups were better than before the treatment ,and the observation group was better than in the control group .Compared with before the treatment ,NIHSS scores were lower in the observation group ,but no significant difference in the control group ,and there was no significant difference between the two groups after the treatment .Conclusions Aerosolized amikacin and ambroxol treatment as an adjuvant therapy can be effective to control pneumonia symptom ,help promoting recovery of neu‐ral and lung function of patients with SAP .
出处
《滨州医学院学报》
2014年第5期321-323,共3页
Journal of Binzhou Medical University
基金
滨州医学院科技计划项目(BY2009KJ42)
